Danaher Corporation Experiences Stock Struggles Despite Strong Fundamentals

With a market cap of $148.5 billion, Danaher Corporation (DHR), based in Washington, D.C., stands as a global leader. The company designs, manufactures, and markets a diverse array of professional, medical, research, and industrial products. It operates through key segments, including Biotechnology, Life Sciences, and Diagnostics, catering to sectors like biopharmaceuticals, healthcare, aerospace, and food safety.

Falling into the “large-cap” category with a valuation above $10 billion, Danaher is recognized for its pioneering role in adopting Kaizen principles. The corporation has expanded significantly through strategic acquisitions, primarily within life sciences, diagnostics, and biotechnology.

Active Investor: FREE newsletter going behind the headlines on the hottest stocks to uncover new trade ideas

 

Recently, shares of this industrial and medical device maker have faced considerable challenges. After reaching a 52-week high of $281.70 in August last year, DHR’s stock has declined by 26.3%. Over the past three months, shares have fallen 13.8%, falling short of the broader S&P 500 Index’s ($SPX) drop of just 1.7% during the same period.

When observed on a year-to-date (YTD) basis, DHR is down 9.5%, significantly trailing the SPX’s gain of 1.1%. Additionally, the company has endured an 18.8% decline over the past 52 weeks, while the SPX delivered a 15.8% return in the same timeframe.

As of late October last year, DHR shares have been trading below their 50-day and 200-day moving averages, indicating a prolonged period of underperformance.

Despite reporting stronger-than-expected Q4 2024 revenue of $6.5 billion, Danaher’s share price dropped 9.7% on January 29. The adjusted earnings per share (EPS) came in at $2.14, which missed the consensus estimate. Additionally, the guidance for Q1 2025 suggests a potential low-single-digit decline in adjusted core sales. The Diagnostics segment has shown particular weakness, with revenue decreasing by 3% year-over-year to $2.6 billion and operating profit falling 18.5% to $624 million.

In comparison, Danaher has performed slightly better than its rival, Thermo Fisher Scientific Inc. (TMO), which has seen a 9.1% decline over the past 52 weeks. However, TMO has experienced a slight increase on a YTD basis.

Despite recent setbacks, analysts retain a bullish outlook on Danaher’s future. Among the 24 analysts monitoring the Stock, DHR holds a consensus rating of “Strong Buy.” Currently, DHR is trading below the average price target of $269.55.

On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.